Johnson & Johnson
NYSE: JNJ
$155.75
+$0.58 (+0.4%)
Closing Price on November 25, 2024
JNJ Articles
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
After Momenta Pharmaceuticals announced that it would be acquired by pharmaceutical giant Johnson & Johnson, the biotechnology company's shares soared on Wednesday.
Published:
Johnson & Johnson has announced that it will launch its human study for its lead vaccine candidate in the United States and Belgium.
Published:
Credit Suisse has assembled its favorite health care recovery stocks for a recovering base of elective surgeries and for the risk of rising hospitalizations that go well beyond COVID-19.
Published:
If you are a bond and income investor now, times are grim. One analyst says that the best income portfolio now very well may be a collection of high-quality stocks that pay dependable dividends.
Published:
Many investors feel like the key stocks in the market have simply gotten away from them, but those fears are perhaps misguided, according to some key analysts.
Published:
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering how they...
Published:
Johnson & Johnson released better than expected quarterly results and guidance before the markets opened on Thursday.
Published:
Here, 24/7 Wall St. offers a preview of what to expect from Delta Air Lines, Netflix, PepsiCo and some of the other most anticipated quarterly results due this week.
Published:
Johnson & Johnson has announced that it will accelerate initiation of its early stage first-in-human clinical trial for the treatment of COVID-19. Shares got a mild boost on Wednesday from the news.
Published:
These five very conservative Dividend Aristocrat stocks may offer nervous investors some shelter from the storm if markets head south again.
Published:
Here are 20 bold companies that have defied the odds by raising their dividends, after already knowing they were facing a very deep recession.
Published:
These five stocks could be big winners if the recovery is W-shaped and we and we return to the March lows before turning higher. They also have had substantial insider buying recently, a good sign...
Published:
Even in the toughest times, some companies still manage to generate dividend growth and prove that they have safe dividends. These 15 companies have announced dividend hikes in April.
Published:
Tuesday's top analyst upgrades and downgrades included AT&T, Cognex, Johnson & Johnson, Keurig Dr Pepper, PayPal, Roku, Shopify, Square, Valero Energy and Walt Disney.
Published: